Publisher: Bentham Science Publishers
E-ISSN: 1873-4286|15|9|983-987
ISSN: 1381-6128
Source: Current Pharmaceutical Design, Vol.15, Iss.9, 2009-03, pp. : 983-987
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. 18F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.
Related content
Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design, Vol. 15, Iss. 9, 2009-03 ,pp. :